Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Fate Therapeutics, Inc. (FATE) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fate Therapeutics, Inc. (FATE) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for April 14th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th:
Apollo Endosurgery, Inc. : This medical technology company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.
Apollo Endosurgery, Inc. Price and Consensus
Apollo Endosurgery, Inc. price-consensus-chart | Apollo Endosurgery, Inc. Quote
Apollo Endosurgery’s shares gained 23.3% over the last one month above the S&P 500’s increase of 1.9%. The company possesses a Momentum Score of B.
Apollo Endosurgery, Inc. Price
Apollo Endosurgery, Inc. price | Apollo Endosurgery, Inc. Quote
Aquestive Therapeutics, Inc. (AQST - Free Report) : This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.8% over the last 60 days.
Aquestive Therapeutics, Inc. Price and Consensus
Aquestive Therapeutics, Inc. price-consensus-chart | Aquestive Therapeutics, Inc. Quote
Aquestive Therapeutics’ shares gained 72% over the last one month. The company possesses a Momentum Score of B.
Aquestive Therapeutics, Inc. Price
Aquestive Therapeutics, Inc. price | Aquestive Therapeutics, Inc. Quote
Fate Therapeutics, Inc. (FATE - Free Report) : This clinical-stage biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.2% over the last 60 days.
Fate Therapeutics, Inc. Price and Consensus
Fate Therapeutics, Inc. price-consensus-chart | Fate Therapeutics, Inc. Quote
Fate Therapeutics’ shares gained 31.4% over the last one month. The company possesses a Momentum Score of B.
Fate Therapeutics, Inc. Price
Fate Therapeutics, Inc. price | Fate Therapeutics, Inc. Quote
Mersana Therapeutics, Inc. (MRSN - Free Report) : This clinical-stage biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.6% over the last 60 days.
Mersana Therapeutics, Inc. Price and Consensus
Mersana Therapeutics, Inc. price-consensus-chart | Mersana Therapeutics, Inc. Quote
Mersana Therapeutics’ shares gained 52.1% over the last one month. The company possesses a Momentum Score of B.
Mersana Therapeutics, Inc. Price
Mersana Therapeutics, Inc. price | Mersana Therapeutics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>